局部辅助放疗对切缘阴性、无淋巴结转移的原发性皮肤鳞状细胞癌的效用评估
该匹配回顾性队列研究比较了手术联合局部辅助放疗(S+ART)与单纯手术(SM)对具有大管径神经侵犯(LCNI)等高危因素的原发性皮肤鳞状细胞癌(cSCC)的疗效。匹配分析纳入62例cSCC(31例S+ART,31例SM),LCNI亚组分析纳入33例(16例S+ART,17例SM)。两种分析中局部复发、转移或疾病死亡均无显著差异,局部复发风险低(8%,7/89)。
要点
- 对于切缘阴性的原发性cSCC,辅助放疗未改善局部复发、转移或疾病死亡。
- 局部复发总体风险低(8%),且部分复发后可有效治疗。
- 既往研究提示命名神经侵犯和≥3条神经的LCNI可能从辅助放疗中获益。
核心结论
- 辅助放疗相比单纯手术未改善结局,因基线复发风险低。
- 既往研究显示命名神经侵犯和≥3条神经的LCNI可从辅助放疗获益。
- 需随机研究界定辅助放疗有获益的cSCC亚组。
研究设计与样本
- 匹配回顾性队列研究,匹配因素包括性别、年龄、免疫状态、手术类型、直径、分化、深度和LCNI。
- 匹配分析纳入62例cSCC(31例S+ART,31例SM)。
- LCNI亚组分析纳入33例cSCC(16例S+ART,17例SM)。
主要发现
- 匹配分析和LCNI分析中局部复发、转移或疾病死亡均无显著差异。
- 局部复发风险低(8%,7/89),其中3例复发后得到有效治疗。
关键数值与推荐
- 局部复发率8%(7/89)。
- 匹配分析样本量62例(31例S+ART,31例SM)。
- LCNI分析样本量33例(16例S+ART,17例SM)。
临床怎么用
- 对于切缘阴性、无淋巴结转移的原发性cSCC,辅助放疗不应常规使用。
- 具有LCNI等高危因素者需个体化评估,参考既往研究对命名神经侵犯和≥3条神经LCNI的提示。
局限性
- 单中心学术机构。
- 非随机化设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Though the National Comprehensive Cancer Network recommends consideration of localized adjuvant radiation after clear-margin surgery for cutaneous squamous cell carcinoma (cSCC) with large-caliber (≥0.1-mm) nerve invasion (LCNI) and other high-risk features, only a single small study has compared surgery plus adjuvant radiation therapy (S+ART) to surgical monotherapy (SM) for cSCC. OBJECTIVE: Compare S+ART to SM for primary cSCCs with LCNI and other risk factors. METHODS: Matched retrospective cohort study of primary cSCCs (matched on sex, age, immune status, type of surgery, diameter, differentiation, depth, and LCNI) treated with S+ART versus SM. A subgroup analysis of cSCCs with LCNI was performed. RESULTS: In total, 62 cSCCs were included in matched analysis (31 S+ART and 31 SM) and 33 cSCCs in the LCNI analysis (16 S+ART and 17 SM). There were no significant differences in local recurrence, metastasis, or death from disease in either analysis. Risk of local recurrence was low (8%, 7/89), with 3 of the local recurrences being effectively treated upon recurrence. LIMITATIONS: Single academic center and nonrandomized design. CONCLUSION: Adjuvant radiation did not improve outcomes compared with SM due to a low baseline risk of recurrence, although adjuvant radiation for named nerve invasion and LCNI of ≥3 nerves has been shown to improve outcomes in a prior study. Randomized studies are needed to define the subset of cSCC for whom adjuvant radiation has utility.
引用
- Ruiz ES, Koyfman SA, Que SKT, et al. Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. J Am Acad Dermatol. 2019. PMID: 31349042. doi:10.1016/j.jaad.2019.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。